The preventive effect of hyoscine butylbromide on catheter-related bladder discomfort in the post-anesthesia care unit

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000662

Enrollment

110

Registered

2013-02-05

Start date

2013-01-15

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Intervention : intravenous administration of hyoscine butylbromide 20mg after the end of surgery, before recovery from general anesthesia Control : no drug will be administered after the end of

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Patients whose Foley catheters are newly placed in the operating room and are planned to be kept for 6 hours or more. 2) Male patients 3) 20- to 75-year-old patients that have 14 Fr. or more sized Foley catheters. 4) American Society of Anesthesiologists class 1 or 2 5) patients from whom informed consents were obtained.

Exclusion criteria

Exclusion criteria: 1) Neurogenic bladder 2) overactive bladder 3) those that are hyper-sensitive or contra-indicated to the study drug 4) those that have central nerveous system or renal disorder 5) those that have neurologic disease

Design outcomes

Primary

Measure	Time frame
incidence and severity of CRBD	—

Secondary

Measure	Time frame
postoperative nausea and vomitting ;Rescue antiemetics;Dry mouth ;Facial flushing ;Blurred vision ;postoperative pain (VAS);rescue analgesic ;Total amount of analgesics including PCA administered for 6 hours after administration of hyoscine butylbromide	—

Countries

Korea, Republic of

Contacts

Public ContactJung-won Hwang

Seoul National University Bundang Hospital

Outcome results